The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …

A hallmark of cancer is the ability of tumor cells to avoid immune destruction. Activated
immune cells in tumor microenvironment (TME) secrete proinflammatory cytokines and …

MAPK signaling inhibitor (MAPKi) therapies show limited efficacy for advanced thyroid
cancers despite constitutive activation of the signaling correlates with disease recurrence …

The RAF inhibitor vemurafenib (PLX4032) increases survival in patients with BRAF-mutant
metastatic melanoma, but has limited efficacy in patients with colorectal cancers. Thyroid …

We generated cell lines resistant to BRAF inhibitors and show that the EGF receptor (EGFR)–
SRC family kinase (SFK)–STAT3 signaling pathway was upregulated in these cells. In …

Advanced human thyroid cancers, particularly those that are refractory to treatment with
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …

Differentiated thyroid cancers are more frequent in women than in men. These different
frequencies may depend on differences in patient's behavior and in thyroid investigations …